Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Response to letter to the editor; ANE-O-03-12-096.

Henriksen EH, Ljøstad U, Tveiten A, Naess H, Thomassen L, Mygland A.

Acta Neurol Scand. 2013 Sep;128(3):e19. doi: 10.1111/ane.12072. No abstract available.

PMID:
23947770
2.

Tissue plasminogen activator (tPA) for ischemic stroke in patients aged ≥80 years.

Zhou C, Zhu L, Wu J, Fang S.

Acta Neurol Scand. 2013 Sep;128(3):e17-8. doi: 10.1111/ane.12073. No abstract available.

PMID:
23947769
3.

Tissue plasminogen activator for acute ischaemic stroke.

Fatovich DM.

Med J Aust. 2008 Apr 21;188(8):489; author reply 490. No abstract available.

PMID:
18429725
4.

Response to letter regarding article, "standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses".

Liao X, Wang Y, Wang Y.

Stroke. 2014 Dec;45(12):e304. doi: 10.1161/STROKEAHA.114.007363. Epub 2014 Oct 23. No abstract available.

5.

Tissue plasminogen activator (tPA) for acute ischaemic stroke: why so much has been made of so little.

Hoffman JR.

Med J Aust. 2003 Oct 6;179(7):333-4. No abstract available.

PMID:
14503891
6.

Letter by Chao et al regarding article, "standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses".

Chao AC, Po HL, Chan L.

Stroke. 2014 Dec;45(12):e303. doi: 10.1161/STROKEAHA.114.007340. Epub 2014 Oct 23. No abstract available.

7.

Door-to-needle times in acute ischemic stroke: how low can we go?

Smith EE, von Kummer R.

Neurology. 2012 Jul 24;79(4):296-7. doi: 10.1212/WNL.0b013e31825d602e. Epub 2012 May 23. No abstract available.

PMID:
22622861
8.

[Thrombolytic therapy with tPA for the treatment of acute stroke. The Standard Treatment with Alteplase to Reverse Stroke study].

Di Pasquale G.

Ital Heart J Suppl. 2000 Jul;1(7):947-8. Italian. No abstract available.

PMID:
10935744
9.

[Treatment of acute ischemic apoplexy].

Andersen G, Krieger DW, Iversen HK.

Ugeskr Laeger. 2009 Mar 23;171(13):1094. Danish. No abstract available.

PMID:
19321089
10.

Thrombolysis for acute ischaemic stroke: revisiting the evidence.

Bailey PM.

Med J Aust. 2003 Oct 6;179(7):388; author reply 388-9. No abstract available.

PMID:
14601632
11.

Thrombolysis for acute ischaemic stroke: revisiting the evidence.

Smith BJ.

Med J Aust. 2003 Oct 6;179(7):386-7; discussion 387. No abstract available.

PMID:
14503907
12.

[Thrombolytic treatment in everyday clinical practice--efficacious and safe?].

Grond M.

Dtsch Med Wochenschr. 2006 Nov;131 Suppl 5:S129-31. Review. German. No abstract available.

PMID:
17089257
13.

Treatment of acute ischemic stroke, Part 1.

Fullerton T.

J Am Pharm Assoc (Wash). 1996 Oct;NS36(10):571-2. Review. No abstract available.

PMID:
8908931
14.
15.

Response to letter regarding article, "Predicting clinical outcomes after thrombolysis using the iScore: results from the Virtual International Stroke Trials Archive".

Saposnik G, Johnston SC, Ovbiagele B; VISTA Collaboration.

Stroke. 2013 Nov;44(11):e155. doi: 10.1161/STROKEAHA.113.003258. Epub 2013 Oct 1. No abstract available.

16.

Intravenous thrombolytic therapy for acute ischemic stroke.

Wechsler LR.

N Engl J Med. 2011 Jun 2;364(22):2138-46. doi: 10.1056/NEJMct1007370. Review. No abstract available.

PMID:
21631326
17.

Repeated MR-based intravenous thrombolysis in a patient with short interval stroke recurrences.

Nicoli F, Faivre A, Squarcioni C, Combaz X, Girard N.

J Neuroradiol. 2011 Oct;38(4):256-8. doi: 10.1016/j.neurad.2010.09.003. Epub 2010 Nov 19. No abstract available.

18.

Should more patients with acute ischaemic stroke receive thrombolytic treatment?

Wardlaw JM, Sandercock PA, Murray V.

BMJ. 2009 Nov 11;339:b4584. doi: 10.1136/bmj.b4584. No abstract available.

PMID:
19906748
19.

Reasons for exclusion from thrombolytic therapy following acute ischemic stroke.

Schestatsky P, Picon PD.

Neurology. 2005 Dec 13;65(11):1844; author reply 1844. No abstract available.

PMID:
16344546
20.

Supplemental Content

Support Center